Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy

NCT06891521 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: QRCH-2025002
• Study Type: interventional
• Target: 123
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.

Conditions

Cancer; Adverse Events

Keywords

Electroacupuncture; immunotherapy; immune-related adverse events (irAEs); malignant tumors

Outcome Measures

Primary Outcomes (1)

• The overall incidence of any grade of immune-related adverse events (irAEs).

  IrAEs are defined as any adverse events potentially related to immune mechanisms that occur during or after ICIs treatment. Adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

  48 weeks.

Secondary Outcomes (16)

• The incidence of Grade ≥3 immune-related adverse events (irAEs).

  48 weeks.

• The time to onset of Grade ≥3 immune-related adverse events (irAEs).

  48 weeks.

• The time to onset of any grade of immune-related adverse events (irAEs).

  48 weeks.

• The incidence of any grade and Grade ≥3 immune-related adverse events (irAEs) associated with ICIs combination therapy.

  48 weeks.

• The incidence of any grade and Grade ≥3 treatment-related adverse events (TRAEs) associated with ICIs combined with chemotherapy.

  48 weeks.

Study Arms (1)

Electroacupuncture group

EXPERIMENTAL

Patients received electroacupuncture therapy on the day before and the first day of each ICIs treatment cycle. Intervention: The patient received electroacupuncture and standard antitumor therapy.

Procedure: Electroacupuncture

Interventions

Electroacupuncture PROCEDURE

Patients received electroacupuncture on the day before and the first day of each ICIs treatment cycle. The electroacupuncture points selected Zusanli (ST36), Quchi (LI11), and Hegu (LI4). Patients will be positioned supine, and the acupuncturist will disinfect the local skin at the acupuncture points using 75% ethanol on cotton balls. A disposable acupuncture needle (0.3mm × 40mm) will be inserted using either a single-hand or double-hand needling technique, with rapid, direct insertion. Once the needle reaches a depth of approximately 0.5 cun, the technique of lifting, thrusting, twirling, and rotating will be applied. After obtaining "de qi", the needles will be retained for 30 minutes. Needling will be performed once every 10 minutes, and the needling technique used will be a balanced reinforcing and reducing method. Electroacupuncture will be applied using a dense-wave form, with a frequency of 2 Hz and an intensity not exceeding 10 mA.

Electroacupuncture group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years, any gender, any nationality.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
• A definitive diagnosis of malignant tumor confirmed by pathology, and no previous treatment with PD-1/PD-L1 inhibitors.
• Patients who are receiving their first treatment with PD-1/PD-L1 inhibitors monotherapy, PD-1/PD-L1 inhibitors combined with anti-angiogenic agents, or combined chemotherapy.
• Expected survival of more than 3 months.
• Normal bone marrow and organ function.
• Premenopausal women must use adequate contraception.
• Written informed consent obtained from the patient prior to enrollment.

You may not qualify if:

• Patients who have previously received or are currently receiving immunotherapy monotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with targeted therapy.
• Patients who have undergone acupuncture, radiotherapy, or surgery within 4 weeks prior to the start of treatment.
• Patients who have received any dose of systemic corticosteroid treatment within 72 hours prior to Day 1 of Cycle 1.
• Patients with active systemic autoimmune diseases within the past 2 years (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with a history of vitiligo or asthma in childhood who have been in complete remission with no intervention in adulthood may be included; subjects requiring bronchodilator medical intervention should be excluded), diagnosed with immunodeficiency or treated with immunosuppressive therapy within the past week, human immunodeficiency virus (HIV) (+), history of non-infectious pneumonia treated with glucocorticoids, pneumonia, active tuberculosis, active hepatitis B or C virus infection, or currently undergoing any systemic treatment for active infections.
• Significant abnormal laboratory values (platelet count, absolute neutrophil count, free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone(TSH), adrenocorticotropic hormone (ACTH), morning cortisol, glycated hemoglobin (HbA1c), C-peptide, autoantibodies, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, prothrombin time/international normalized ratio (PT/INR), serum bilirubin, amylase, lipase, CRP).
• Skin diseases or inflammatory skin reactions that may interfere with clinical trial outcomes.
• Patients who have developed lymphedema at the site of acupuncture stimulation after receiving any acupuncture treatment.
• Patients who fear electroacupuncture stimulation or are allergic to stainless steel needles.
• Patients with psychiatric disorders, or those taking any antipsychotic or antidepressant medications.
• Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss.
• Patients with diabetes.
• Any other diseases, metabolic disorders, physical examination results, or clinical laboratory findings that raise reasonable suspicion of a disease or condition that may affect the interpretation of the outcomes or put the participant at high risk for treatment complications.
• Pregnant or breastfeeding women, or women planning to become pregnant during the study period.
• Severe medical or psychiatric conditions.
• Any patient deemed unsuitable for enrollment by the investigator.

Sponsors & Collaborators

• Qinghai Red Cross Hospital: lead

Study Sites (1)

Qinghai, China, Qinghai Red Cross Hospital

Xining, Qinghai, 810000, China

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Electroacupuncture

Intervention Hierarchy (Ancestors)

Combined Modality Therapy; Therapeutics; Acupuncture Therapy; Complementary Therapies; Electric Stimulation Therapy; Physical Therapy Modalities; Rehabilitation; Transcutaneous Electric Nerve Stimulation; Analgesia; Anesthesia and Analgesia; Anesthesia

Central Study Contacts

QiuXia Dong, Dr.

CONTACT

+86 0971-8267613; 2816278916@qq.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 27, 2025
• First Posted: March 24, 2025
• Study Start: March 20, 2025
• Primary Completion (Estimated): March 1, 2027
• Study Completion (Estimated): June 1, 2028
• Last Updated: March 24, 2025

Record last verified: 2025-03

Locations

CN (1)